Aurora Cannabis (NASDAQ:ACB) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Aurora Cannabis (NASDAQ:ACB) posted its quarterly earnings data on Thursday. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.14, Zacks reports. Aurora Cannabis had a negative net margin of 33.57% and a positive return on equity of 0.10%. The firm had revenue of $60.98 million during the quarter, compared to analyst estimates of $54.42 million.

Here are the key takeaways from Aurora Cannabis’ conference call:

• Aurora said fiscal 2026 was a strong year, with net revenue up 11% to CAD 321 million, adjusted EBITDA up 32% to CAD 54 million, and adjusted net income improving by more than CAD 12 million versus the prior year.
• The company emphasized its global medical cannabis leadership, noting that about 55% of revenue came from outside Canada and that it holds leading positions in Canada, Germany, Australia, and Poland.
• Aurora is intentionally exiting lower-margin Canadian consumer and plant propagation businesses to reallocate capital toward higher-return international medical opportunities, though management said this will create a near-term revenue reset in FY2027.
• The company highlighted the Safari Flower acquisition and the Leuna expansion in Germany as steps to expand EU GMP capacity, with Safari expected to contribute positive adjusted EBITDA in FY2027 and more meaningfully thereafter.
• FY2027 guidance calls for lower revenue and lower annual adjusted EBITDA, mainly because of Canada’s reimbursed pricing change, which management said will reduce Canadian medical revenue and gross profit but be partly offset by international growth.

Aurora Cannabis Stock Down 1.3%

Shares of ACB stock opened at $3.04 on Friday. The stock’s 50 day simple moving average is $3.45 and its 200 day simple moving average is $3.84. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.48 and a current ratio of 3.06. Aurora Cannabis has a twelve month low of $2.73 and a twelve month high of $6.66. The company has a market capitalization of $186.47 million, a price-to-earnings ratio of -1.95 and a beta of 0.53.

Analyst Ratings Changes

Several brokerages recently commented on ACB. Weiss Ratings raised Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Wall Street Zen raised shares of Aurora Cannabis from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold”.

Hedge Funds Weigh In On Aurora Cannabis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACB. Headlands Technologies LLC bought a new stake in shares of Aurora Cannabis in the fourth quarter valued at about $58,000. Northwestern Mutual Wealth Management Co. increased its stake in Aurora Cannabis by 1,808.9% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,518 shares of the company’s stock valued at $63,000 after acquiring an additional 9,967 shares during the period. Engineers Gate Manager LP bought a new position in Aurora Cannabis during the second quarter valued at about $68,000. Squarepoint Ops LLC acquired a new position in Aurora Cannabis in the 4th quarter valued at approximately $69,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Aurora Cannabis in the 3rd quarter valued at approximately $100,000. Institutional investors and hedge funds own 47.63% of the company’s stock.

Aurora Cannabis Company Profile

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.